Catecholamine metabolism

Catecholamine metabolism is a fundamental biochemical pathway comprising the synthesis, release, reuptake, and degradation of the catecholamines dopamine, norepinephrine, and epinephrine[1][5][7][8]. Synthesis begins with tyrosine, converted sequentially via tyrosine hydroxylase, DOPA decarboxylase, dopamine β-hydroxylase, and phenylethanolamine N-methyltransferase[1][4][7]. Breakdown occurs through two primary enzymes, monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT), yielding diagnostic metabolites (VMA, HVA)[3][5][6]. Dysregulation of these enzymatic steps is implicated in neurological, cardiovascular, and endocrine disorders[1][2][3]. Drugs modulating this pathway target specific enzymes or receptors to alter neurotransmitter levels or catecholaminergic signaling.

Other names

Catecholamine metabolic pathwayCatecholamine biosynthesis and degradation

Inhibition of enzymatic breakdown (MAOI, COMT inhibitor: prolong catecholamine action); Inhibition of catecholamine synthesis (AMPT blocks tyrosine hydroxylase); Precursor supplementation (levodopa increases dopamine synthesis); Blockade of downstream catecholamine receptors (alpha/beta blockers suppress physiological effects of pathway activity).